Business Context and Reporting Period
Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 8-K (Current Report)
Date: April 27, 2026
Context: The filing discloses the announcement of clinical data from the COMPANION-002 randomized Phase 2/3 study of tovecimig (formerly CTX-009) in combination with paclitaxel for patients with advanced biliary tract cancer (BTC) in the second-line setting.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the results of the COMPANION-002 study involving 168 patients randomized 2:1 to tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). Key outcomes include:
- Primary Endpoint (ORR): Met. Tovecimig combination achieved a 17.1% Overall Response Rate (ORR) versus 5.3% for paclitaxel alone (p=0.031).
- Progression-Free Survival (PFS): Statistically significant improvement in median PFS for the combination arm (4.7 months) compared to paclitaxel alone (2.6 months) (HR=0.44, p<0.0001).
- Overall Survival (OS): The study did not meet the OS secondary endpoint. Median OS was 8.9 months for the combination arm versus 9.4 months for the control arm (HR=1.05, p=0.78). The company attributes this to high crossover (54% of control patients) and prolonged survival of crossover patients.
- Crossover Analysis: Patients who crossed over from paclitaxel to tovecimig showed a statistically significant improvement in median OS (12.8 months) compared to non-crossover patients (6.1 months).
- Safety: Tovecimig was generally well tolerated. Most common Grade 3+ adverse events were hypertension (44%) and neutropenia (36%).
Guidance, Outlook, and Risks
Management Commentary and Next Steps:
- Compass intends to meet with the U.S. Food and Drug Administration (FDA) in the coming months to discuss these data.
- The company plans to submit a Biologics License Application (BLA) following regulatory discussions.
- Complete dataset presentation is expected at a medical conference later in 2026.
- Regulatory Uncertainty: The failure to meet the OS endpoint due to crossover may impact regulatory approval pathways, though the company is proceeding with FDA discussions.
- Funding: Forward-looking statements highlight the inherent uncertainty of raising additional funding required to continue business and product development plans.
- Development Risks: Risks include the ability to complete clinical trials, obtain approvals, and commercialize product candidates in a competitive market.
Investor Verification Checklist
- Verify the FDA's response to the upcoming meeting regarding the BLA submission strategy given the OS endpoint miss.
- Confirm the company's current cash runway and capital raise plans to support the BLA submission and potential commercialization.
- Review the full presentation (Exhibit 99.2) for detailed subgroup analyses and safety data not fully captured in the summary.
- Monitor the timing and content of the upcoming medical conference presentation for additional data insights.